One of the biggest concerns for people diagnosed with uveal melanoma is whether the cancer will spread beyond the eye. While many patients are successfully treated for their eye tumor, some later develop metastatic disease, most commonly in the liver. Predicting who is at the highest risk has been an important area of research for many years.
A new study from researchers at Severance Eye Hospital and KAIST in South Korea offers encouraging progress toward answering that question. By studying the complete genetic makeup of uveal melanoma tumors, researchers identified important genetic changes that may help doctors predict a patient’s risk of metastasis with greater accuracy than current methods.
The study focused on two key findings. First, researchers found that abnormalities in the BAP1 gene were strongly linked to metastatic disease. Most patients whose cancer later spread carried these BAP1 changes, while they were much less common in patients whose cancer remained confined to the eye.
The research team also discovered that changes involving part of chromosome 1 provided additional information about metastasis risk. By combining these two genetic markers, they developed a new risk classification system that separated patients into four groups ranging from very low to very high risk.
Although this research will need additional validation before becoming part of routine clinical care, the results are promising. More accurate risk prediction could allow physicians to tailor follow-up care based on each patient’s individual risk. Those at higher risk may benefit from more frequent imaging, closer surveillance, or consideration for clinical trials as new therapies continue to emerge.
Another fascinating discovery was that many of the genetic changes associated with uveal melanoma may begin decades before the disease is diagnosed. This finding helps researchers better understand how the cancer develops over time and could eventually lead to earlier detection strategies.
It is also significant that this study included patients from an Asian population. Much of what is currently known about uveal melanoma genetics comes from studies in Western populations. Expanding research across diverse populations helps ensure that future treatments and prediction tools are effective for patients worldwide.
While no single genetic test can predict the future with complete certainty, studies like this move the field one step closer to more personalized care. Every new discovery improves our understanding of uveal melanoma and brings hope that patients can receive more individualized monitoring, earlier intervention, and better outcomes.
How A Cure In Sight Can Help
Learning about new research can bring both hope and questions after an ocular melanoma diagnosis. A Cure In Sight is committed to helping patients and families understand the latest scientific advances by providing trusted educational resources, information about clinical trials, physician referrals, financial assistance programs, and opportunities to connect with others who have experienced this rare disease. As research continues to improve our understanding of uveal melanoma, we remain dedicated to supporting patients every step of the way while working toward better treatments—and ultimately, a cure.